The transdermal drug delivery system market is expected to grow from US$ 37,230.28 million in 2022 to US$ 51,949.74 million by 2030; it is anticipated to record a CAGR of 4.3% from 2022 to 2030. Strategic initiatives by manufacturers will likely remain a key trend in the market.
The increasing prevalence of chronic diseases, growing demand for noninvasive drug delivery devices, and high demand for self-administration of drugs are the key driving factors behind the market growth. Furthermore, adopting 3D printing technology and smart patches will likely offer opportunities to the transdermal drug delivery systems market in the coming years.
Cardiovascular diseases (CVDs) such as angina, atherosclerosis, pectoris, and acute myocardial infarction are among the common causes of mortality in the world. According to the WHO, CVDs are the major cause of ~17.9 million deaths worldwide every year. Many medicines are commercially available for the treatment of CVDs, but conventional capsules and tablets are unable to control the ailment effectively. This underlines the need for novel drug delivery systems providing prolonged drug bioavailability and targeted drug delivery to the affected areas of the cardiovascular system. Transdermal drug delivery systems offer many advantages over regular orally administered drugs to treat cardiovascular diseases. Transdermal patches, encompassing drug particles, are applied on the skin surface. A cardiac patch provides an excellent platform for cell engraftment improvement. For example, a vascularized cardiac patch developed recently shows promising potential for treating ischemic heart injuries. Nitroglycerin transdermal patches are used to prevent angina (chest pain) episodes in people with coronary artery disease. They work by relaxing the blood vessels and reducing the heart's stress, lowering the need for oxygen. However, these patches cannot be used to treat angina attacks that have already begun.
Traditional drug delivery techniques such as intramuscular, intravenous, and rectal drug administration are not preferred by specific patient populations, mainly due to the pain and complexities associated with them. With the improvements in medical science and definite drug delivery technologies, noninvasive drug delivery systems are now set to compete with the traditional method of injectable drug administration. The noninvasive drug delivery systems include drug delivery via oral, topical, transdermal-active (device-aided enhanced penetration), and transdermal-passive; transocular membrane, transmucosal membrane, and alveolar membrane from inhaled medication. Transdermal drug delivery is advantageous in many ways over the oral route of administration. In particular, it evades the first-pass mechanism of the liver, which can otherwise impulsively metabolize drugs.
A transdermal drug administration route is novel and one of the reliable means of sustained drug delivery. With significant research being conducted in this field and the increasing interest of researchers in this form of drug delivery, many transdermal patches are likely to reach the marketplace in the future. Transdermal patches are used to deliver drugs such as nicotine, fentanyl, nitroglycerin, and clonidine to treat various medical conditions. Recently, these patches have been explored to deliver biologics in various applications. Smart patches are equipped with sensors and other technologies to monitor patient conditions and adjust drug delivery accordingly. In January 2023, a lead scientist at Swansea University developed a new smart patch to detect proinflammatory biomarkers of neurodegenerative diseases such as Parkinson's and Alzheimer's using the microneedle technology. These smart patches comprise numerous microneedles designed to penetrate the skin barrier in a minimally invasive manner, followed by monitoring the biomarkers of clinical significance. They can be self-administered for point-of-care diagnosis at general practices or home. This innovative research can potentially change the landscape of early neurodegenerative disease detection.
Key segments that contributed to the derivation of the transdermal drug delivery system market analysis are product and end user.
The geographic scope of the transdermal drug delivery system market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
The US is the largest market for transdermal drug delivery systems in North America. According to the American Heart Association (AHA), cardiovascular disease (CVD) remains the leading cause of death in the US. According to the CDC, in 2021, CVD accounted for ~695,000 deaths and ~1 in 5 deaths in the US. The rising prevalence of cardiovascular disease, diabetes, chronic pain conditions, and other chronic diseases drives the demand for effective and convenient treatment options. Medical patches offer a noninvasive and patient-friendly approach to deliver medication and manage symptoms associated with these chronic conditions. Ongoing advancements in TDDS, such as wearable sensors and flexible electronics, contribute to the growth of the transdermal drug delivery system market. These advancements allow for more accurate dosing, patient monitoring, and compliance. According to a report titled "Recent advances in transdermal drug delivery systems," published by Biomaterials Research in 2021, microneedles attract significant attention among TDDS modalities, which overcome the limitations of the existing simple application type and patch-type needles by combining the advantages of microneedles to obtain higher treatment efficiency and effects. Advances in these TDDS can provide the driving force for controlling the prevalence of cardiovascular and central nervous system diseases, diabetes, neuromuscular diseases, and infectious and localized infectious diseases..
The regional trends and factors influencing the Transdermal Drug Delivery System Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Transdermal Drug Delivery System Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 37,230.28 Million |
| Market Size by 2030 | US$ 51,949.74 Million |
| Global CAGR (2022 - 2030) | 4.3% |
| Historical Data | 2020-2021 |
| Forecast period | 2022-2030 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Transdermal Drug Delivery System Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Transdermal Drug Delivery System Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Transdermal Drug Delivery System Market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the transdermal drug delivery system market are listed below:
The “Transdermal Drug Delivery System Market Size and Forecast (2020–2030)” report provides a detailed analysis of the market covering below areas:
The market is expected to register a CAGR of 4.3% during 2023–2031.
Novartis AG, GSK Plc, Viatris Inc, Boehringer Ingelheim International GmbH, Lavipharm SA, Hisamitsu Pharmaceutical Co Inc, Johnson & Johnson, Luye Pharma Group Ltd, Purdue Pharma LP.
Strategic initiatives by manufacturers will likely remain a key trend in the market.
The increasing prevalence of chronic diseases, growing demand for noninvasive drug delivery devices, and high demand for self-administration of drugs are the key driving factors behind the market growth.
North America dominated the transdermal drug delivery system market in 2023